{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:52:54Z","timestamp":1789411974956,"version":"build-2803163510"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008973","name":"University of Kurdistan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ijbiomac.2025.143557","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T14:34:12Z","timestamp":1745678052000},"page":"143557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"P4","title":["T-cell immunoglobulin and ITIM domain as a target in combo anti-PD-(L)1 cancer therapy"],"prefix":"10.1016","volume":"310","author":[{"given":"Keywan","family":"Mortezaee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.143557_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110207","article-title":"Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8+ T cells showed synergistic effects on improved disease-free survival in treatment-na\u00efve CRC patients","volume":"119","author":"Meyiah","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114890","article-title":"B7-H3 immunoregulatory roles in cancer","volume":"163","author":"Mortezaee","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.143557_bb0015","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jcmgh.2021.03.003","article-title":"TIGIT and PD1 co-blockade restores ex vivo functions of human tumor-infiltrating CD8+ T cells in hepatocellular carcinoma","volume":"12","author":"Ge","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143557_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-022-01621-4","article-title":"Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer","volume":"20","author":"Hu","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143557_bb0025","doi-asserted-by":"crossref","first-page":"1873607","DOI":"10.1080\/2162402X.2021.1873607","article-title":"Addition of anti-TIM3 or anti-TIGIT antibodies to anti-PD1 blockade augments human T cell adoptive cell transfer","volume":"10","author":"Martinez","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0030","first-page":"1","article-title":"DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer","volume":"10","author":"Sasidharan Nair","year":"2018","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0035","doi-asserted-by":"crossref","unstructured":"S. Jin, Z. Shang, W. Wang, C. Gu, Y. Wei, Y. Zhu, C. Yang, T. Zhang, Y. Zhu, Y. Zhu, Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study, Journal of Immunotherapy (Hagerstown, Md.: 1997) 46(4) (2023) 154.","DOI":"10.1097\/CJI.0000000000000466"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.143557_bb0040","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.143557_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106484","article-title":"Prioritizing exhausted T cell marker genes highlights immune subtypes in pan-cancer","volume":"26","author":"Zhang","year":"2023","journal-title":"Iscience"},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1096341","article-title":"Integrated bioinformatic analysis and cell line experiments reveal the significant role of the novel immune checkpoint TIGIT in kidney renal clear cell carcinoma","volume":"13","author":"Xia","year":"2023","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.143557_bb0055","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jiph.2023.01.019","article-title":"Clinical significance of immune checkpoint proteins in HPV-infected cervical cancer","volume":"16","author":"Zou","year":"2023","journal-title":"J. Infect. Public Health"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143557_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112260","article-title":"TIGIT presents earlier expression dynamic than PD-1 in activated CD8+ T cells and is upregulated in non-small cell lung cancer patients","volume":"396","author":"Hu","year":"2020","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0065","article-title":"CD226 identifies functional CD8+ T cells in the tumor microenvironment and predicts a better outcome for human gastric cancer","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143557_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-020-00638-2","article-title":"Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT\/PVR","volume":"18","author":"Zhou","year":"2020","journal-title":"Cell Commun. Signaling"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143557_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-022-03480-x","article-title":"Blocking TIGIT\/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer","volume":"20","author":"Liu","year":"2022","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143557_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000266","article-title":"Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity","volume":"8","author":"Reches","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.143557_bb0085","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1002\/cam4.2976","article-title":"TIGIT enhances CD4+ regulatory T-cell response and mediates immune suppression in a murine ovarian cancer model","volume":"9","author":"Chen","year":"2020","journal-title":"Cancer Med."},{"issue":"7_Supplement","key":"10.1016\/j.ijbiomac.2025.143557_bb0090","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1158\/1538-7445.AM2023-3477","article-title":"Maximizing the outcome of CD226 stimulation through targeting beyond TIGIT signaling with combination and multi-specific approaches for cancer immunotherapy","volume":"83","author":"Stephen","year":"2023","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.143557_bb0095","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen\u2013specific CD8+ T cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.143557_bb0100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12032-022-01837-2","article-title":"Extracellular vesicle-based checkpoint regulation and immune state in cancer","volume":"39","author":"Mortezaee","year":"2022","journal-title":"Med. Oncol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.143557_bb0105","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1158\/1078-0432.CCR-20-2725","article-title":"PET imaging of TIGIT expression on tumor-infiltrating LymphocytesImmunoPET imaging of TIGIT","volume":"27","author":"Shaffer","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143557_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-023-01182-7","article-title":"Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase\u2013deficient renal cell carcinoma","volume":"15","author":"Liang","year":"2023","journal-title":"Genome Med."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1143266","article-title":"Identification of a novel peptide targeting TIGIT to evaluate immunomodulation of 125I seed brachytherapy in HCC by near-infrared fluorescence","volume":"13","author":"Zeng","year":"2023","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.143557_bb0120","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S1556-0864(23)00420-3","article-title":"166P investigating the correlation between circulating tumor cell (CTC) detection and immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)","volume":"18","author":"Agelaki","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"17","key":"10.1016\/j.ijbiomac.2025.143557_bb0125","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.3390\/cancers14174261","article-title":"Defining the immune checkpoint landscape in human colorectal Cancer highlights the relevance of the TIGIT\/CD155 Axis for optimizing immunotherapy","volume":"14","author":"Ducoin","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143557_bb0130","first-page":"1","article-title":"DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer","volume":"10","author":"Sasidharan Nair","year":"2018","journal-title":"Clin. Epigenetics"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.143557_bb0135","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1674605","article-title":"Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer","volume":"8","author":"Stamm","year":"2019","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.143557_bb0140","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1053\/j.gastro.2020.03.074","article-title":"Hepatocellular carcinoma cells up-regulate PVRL1, stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice","volume":"159","author":"Chiu","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.143557_bb0145","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/08820139.2020.1758130","article-title":"Upregulation of TIGIT and PD-1 in colorectal Cancer with mismatch-repair deficiency","volume":"50","author":"Zhou","year":"2021","journal-title":"Immunol. Investig."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.143557_bb0150","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/odi.13703","article-title":"Dysfunctional role of elevated TIGIT expression on T cells in oral squamous cell carcinoma patients","volume":"27","author":"Liu","year":"2021","journal-title":"Oral Dis."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.143557_bb0155","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/2326-6066.CIR-18-0725","article-title":"Blockade of TIGIT\/CD155 signaling reverses T-cell exhaustion and enhances antitumor capability in head and neck squamous cell CarcinomaBlockade of TIGIT\/CD155 signaling in HNSCC","volume":"7","author":"Wu","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0160","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.3389\/fphar.2021.801493","article-title":"Targeting TIGIT inhibits bladder cancer metastasis through suppressing IL-32","volume":"12","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"14","key":"10.1016\/j.ijbiomac.2025.143557_bb0165","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121157","article-title":"CD226 opposes TIGIT to disrupt Tregs in melanoma","volume":"3","author":"Fourcade","year":"2018","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.143557_bb0170","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100884","article-title":"Heterogeneous expression of predictive biomarkers PD-L1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: a challenge for clinical biomarker testing","volume":"38","author":"Kolb","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.molimm.2019.11.008","article-title":"Carboplatin chemoresistance is associated with CD11b+\/Ly6C+ myeloid release and upregulation of TIGIT and LAG3\/CD160 exhausted T cells","volume":"118","author":"Anestakis","year":"2020","journal-title":"Mol. Immunol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.143557_bb0185","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s13402-022-00667-8","article-title":"Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy","volume":"45","author":"Mortezaee","year":"2022","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119627","article-title":"Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives","volume":"277","author":"Mortezaee","year":"2021","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.143557_bb0195","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1002\/eji.201243072","article-title":"Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR","volume":"43","author":"Stanietsky","year":"2013","journal-title":"Eur. J. Immunol."},{"issue":"7_Supplement","key":"10.1016\/j.ijbiomac.2025.143557_bb0200","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1538-7445.AM2023-2908","article-title":"TIGIT knockout enhances anti-tumor response of natural killer cells and prevents fratricide when combined with therapeutic ADCC-competent TIGIT antibodies","volume":"83","author":"Hasan","year":"2023","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.143557_bb0205","doi-asserted-by":"crossref","first-page":"2203699","DOI":"10.1002\/advs.202203699","article-title":"The single-cell landscape of Intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast Cancer","volume":"10","author":"Zou","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0210","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1007\/s00262-021-02886-8","article-title":"TIGIT promotes CD8+ T cells exhaustion and predicts poor prognosis of colorectal cancer","volume":"70","author":"Liang","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"7_Supplement","key":"10.1016\/j.ijbiomac.2025.143557_bb0215","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1158\/1538-7445.AM2023-4121","article-title":"Heterogenous cellular responses to GITR and TIGIT immunotherapy in the human gastrointestinal tumor microenvironment","volume":"83","author":"Sathe","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0220","unstructured":"V.R.A. Febles, Y. Hao, A. Ahsan, J. Wu, Y. Qian, H. Zhong, S. Loeb, D.V. Makarov, H. Lepor, J. Wysock, Single-cell analysis of localized prostate cancer patients links high Gleason score with an immunosuppressive profile, Prostate."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143557_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-023-10836-z","article-title":"Tumor-infiltrating CD36+ CD8+ T cells determine exhausted tumor microenvironment and correlate with inferior response to chemotherapy in non-small cell lung cancer","volume":"23","author":"Ao","year":"2023","journal-title":"BMC Cancer"},{"issue":"22","key":"10.1016\/j.ijbiomac.2025.143557_bb0230","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1158\/0008-5472.CAN-17-0381","article-title":"CD155T\/TIGIT signaling regulates CD8+ T-cell metabolism and promotes tumor progression in human gastric CancerCD155\/TIGIT regulates T-cell metabolism in gastric Cancer","volume":"77","author":"He","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0235","series-title":"TIGIT Induces (CD3+) T Cell Dysfunction in Colorectal Cancer by Inhibiting Glucose Metabolism","author":"Chandra","year":"2022"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.143557_bb0240","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41423-023-00978-2","article-title":"CD8+ CD226high T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery","volume":"20","author":"Viot","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0245","doi-asserted-by":"crossref","unstructured":"Y. Park, H.-s. Jin, CD226hiCD8+ T cells are a prerequisite for anti-TIGIT immunotherapy, J. Immunol. 204(1_Supplement) (2020) 165.10-165.10.","DOI":"10.4049\/jimmunol.204.Supp.165.10"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.143557_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2020.151915","article-title":"TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer","volume":"225","author":"Xu","year":"2020","journal-title":"Immunobiology"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.143557_bb0255","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/biom11050706","article-title":"Repositioning azelnidipine as a dual inhibitor targeting CD47\/SIRP\u03b1 and TIGIT\/PVR pathways for cancer immuno-therapy","volume":"11","author":"Zhou","year":"2021","journal-title":"Biomolecules"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.143557_bb0260","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-18-4011","article-title":"Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-na\u00efve melanoma patients: implications for clinical TrialsNovel immune targets in melanoma","volume":"25","author":"Edwards","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0265","doi-asserted-by":"crossref","unstructured":"M. Heiduk, A. Klimova, C. Reiche, D. Digomann, C. Beer, D.E. Aust, M. Distler, J. Weitz, A.M. Seifert, L. Seifert, TIGIT expression delineates T cell populations with distinct functional and prognostic impact in pancreatic cancer, Clinical Cancer Research (2023) CCR-23-0258.","DOI":"10.1158\/1078-0432.c.6675230.v2"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.143557_bb0270","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1158\/2326-6066.CIR-22-0121","article-title":"Tissue-resident memory T cells in pancreatic ductal adenocarcinoma Coexpress PD-1 and TIGIT and functional inhibition is reversible by dual antibody blockade","volume":"11","author":"Pearce","year":"2023","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.143557_bb0275","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/hep.31466","article-title":"Transcriptome profiling identifies TIGIT as a marker of T-cell exhaustion in liver cancer","volume":"73","author":"Ostroumov","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143557_bb0280","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ygyno.2020.04.689","article-title":"The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers","volume":"158","author":"Smazynski","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"14","key":"10.1016\/j.ijbiomac.2025.143557_bb0285","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1158\/1078-0432.CCR-19-3925","article-title":"Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic MelanomaCD155 and resistance to immune checkpoint blockade","volume":"26","author":"Lepletier","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120988","article-title":"Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis","volume":"275","author":"Chen","year":"2021","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.143557_bb0295","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003134","article-title":"TIGIT\/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment","volume":"9","author":"Kawashima","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.143557_bb0300","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1007\/s00262-022-03182-9","article-title":"Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer","volume":"71","author":"Thibaudin","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.143557_bb0305","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002836","article-title":"Increased coexpression of PD-L1 and TIM3\/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma","volume":"9","author":"Wang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105472","article-title":"TIGIT\/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells","volume":"121","author":"Mao","year":"2021","journal-title":"Oral Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination","volume":"7","author":"Grapin","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143557_bb0320","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1038\/s41598-023-29724-4","article-title":"Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy","volume":"13","author":"Mori","year":"2023","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.143557_bb0325","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41416-022-01703-y","article-title":"TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer","volume":"126","author":"Liu","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0330","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.canlet.2020.11.035","article-title":"TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer","volume":"499","author":"Han","year":"2021","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.143557_bb0335","article-title":"TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM","volume":"7","author":"Hung","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0340","doi-asserted-by":"crossref","unstructured":"W.A. Freed-Pastor, L.J. Lambert, Z.A. Ely, N.B. Pattada, A. Bhutkar, G. Eng, K.L. Mercer, A.P. Garcia, L. Lin, W.M. Rideout, The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer, Cancer Cell 39(10) (2021) 1342\u20131360. e14.","DOI":"10.1016\/j.ccell.2021.07.007"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.143557_bb0345","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003667","article-title":"Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer","volume":"10","author":"Wang","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.143557_bb0350","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/vaccines9010064","article-title":"Tumor-infiltrating lymphoid cells in colorectal cancer patients with varying disease stages and microsatellite instability-high\/stable tumors","volume":"9","author":"Toor","year":"2021","journal-title":"Vaccines"},{"issue":"7_Supplement","key":"10.1016\/j.ijbiomac.2025.143557_bb0355","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1538-7445.AM2023-644","article-title":"Gut microbiota-derived metabolites as regulators of immunity in pre-cancer","volume":"83","author":"Mohseni","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0360","doi-asserted-by":"crossref","unstructured":"H.J. Cho, S. Richard, A. Lesokhin, N. Biran, B. Paul, R. Vij, M. Pianko, D. Doxie, M. Martillo, K. Wozniak, Abstract CT262: durable responses following anti-TIGIT (BMS-986207) and anti-LAG3 (BMS-980616) in combination with pomalidomide in relapsed myeloma: MMRF MyCheckpoint trial, Cancer Res. 83(8_Supplement) (2023) CT262-CT262.","DOI":"10.1158\/1538-7445.AM2023-CT262"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.143557_bb0365","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.143557_bb0370","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen\u2013specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0375","article-title":"An fc-competent anti-human TIGIT blocking antibody ociperlimab (BGB-A1217) elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0380","doi-asserted-by":"crossref","unstructured":"J.C. Bendell, P. Bedard, Y.-J. Bang, P. LoRusso, S. Hodi, M. Gordon, S. D'Angelo, S. D'Angelo, J. Desai, E. Garralda, Abstract CT302: phase Ia\/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors, Cancer Res. 80(16_Supplement) (2020) CT302-CT302.","DOI":"10.1158\/1538-7445.AM2020-CT302"},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0385","series-title":"ARC-7: Randomized Phase 2 Study of Domvanalimab+ Zimberelimab\u00b1Etrumadenant Versus Zimberelimab in First-Line, Metastatic, PD-L1-High Non-small Cell Lung cancer (NSCLC)","author":"Johnson","year":"2022"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.143557_bb0390","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-21-2780","article-title":"A phase 1a\/b open-label, dose-escalation study of etigilimab alone or in combination with nivolumab in patients with locally advanced or metastatic solid tumors","volume":"28","author":"Mettu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0395","series-title":"Phase 2 KEYNOTE-057 Cohort C","author":"Shore","year":"2023"},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0400","article-title":"158P triple blockade of the DNAM-axis with COM701+ BMS-986207+ nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant OVCA","volume":"16","author":"Moroney","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0405","article-title":"Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody","volume":"28","author":"Shirasuna","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"issue":"7_Supplement","key":"10.1016\/j.ijbiomac.2025.143557_bb0410","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1158\/1538-7445.AM2023-593","article-title":"Bispecific antibody against TIGIT and PVRIG enhances antitumor immunity","volume":"83","author":"Liang","year":"2023","journal-title":"Cancer Res."},{"issue":"7_Supplement","key":"10.1016\/j.ijbiomac.2025.143557_bb0415","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1158\/1538-7445.AM2023-6361","article-title":"A preclinical model of acquired anti-PD-1 resistance is responsive to SEA-TGT, an effector-function enhanced anti-TIGIT monoclonal antibody","volume":"83","author":"Gruber","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0420","article-title":"In situ STING-activating Nanovaccination with TIGIT blockade for enhanced immunotherapy of anti-PD-1-resistant tumors","volume":"2300171","author":"Zhang","year":"2023","journal-title":"Adv. Mater."},{"issue":"17","key":"10.1016\/j.ijbiomac.2025.143557_bb0425","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2117065119","article-title":"Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155\/TIGIT axis","volume":"119","author":"Ozmadenci","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0430","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1016\/j.annonc.2021.06.012","article-title":"LBA-5 phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer","volume":"32","author":"Wainberg","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0435","article-title":"126P AdvanTIG-105: phase Ib dose-expansion study of ociperlimab (OCI)+ tislelizumab (TIS) in patients (pts) with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer (NSCLC)","volume":"16","author":"Frentzas","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.143557_bb0440","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer\u2606","volume":"33","author":"Niu","year":"2022","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.143557_bb0445","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0450","doi-asserted-by":"crossref","unstructured":"R. Dummer, C. Robert, R.A. Scolyer, J.M. Taube, M.T. Tetzlaff, A. Hill, J.-J. Grob, D.C. Portnoy, C. Lebbe, M.A. Khattak, Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro)+ vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma, Cancer Res. 83(8_Supplement) (2023) CT002-CT002.","DOI":"10.1158\/1538-7445.AM2023-CT002"},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0455","series-title":"TROPHY-U-01 Cohort 6: Sacituzumab Govitecan (SG), SG plus Zimberelimab (ZIM), SG plus ZIM plus Domvanalimab (DOM), or Carboplatin (CARBO)+ Gemcitabine (GEM) in Cisplatin-Ineligible Patients (Pts) with Treatment-Naive Metastatic Urothelial cancer (mUC)","author":"Duran","year":"2023"},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0460","series-title":"COM701 with or without Nivolumab: Results of an Ongoing Phase 1 Study of Safety, Tolerability and Preliminary Antitumor Activity in Patients with Advanced Solid Malignancies (NCT03667716)","author":"Vaena","year":"2021"},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0465","article-title":"159P COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant epithelial ovarian cancer","volume":"16","author":"Yeku","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0470","article-title":"148P AdvanTIG-105: phase Ib dose-expansion study of ociperlimab (OCI)+ tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)","volume":"16","author":"Zhang","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0475","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1016\/j.annonc.2021.06.011","article-title":"LBA-4 initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G\/GEJ) cancer","volume":"32","author":"Janjigian","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143557_bb0480","doi-asserted-by":"crossref","unstructured":"C. Shemesh, Y. Wang, A. An, H. Ding, P. Chan, Q. Liu, Y.-W. Chen, B. Wu, Q. Wu, X. Wang, Abstract CT266: Chinese race and origin have no clinically meaningful effect on tiragolumab and atezolizumab pharmacokinetics and safety in patients with advanced solid tumors, Cancer Res. 83(8_Supplement) (2023) CT266-CT266.","DOI":"10.1158\/1538-7445.AM2023-CT266"},{"issue":"7_Supplement","key":"10.1016\/j.ijbiomac.2025.143557_bb0485","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1158\/1538-7445.AM2023-6368","article-title":"Preclinical pharmacology and safety studies of ZG005: an anti-PD-1\/TIGIT bispecific mAb in a phase I clinical trial for advanced tumors","volume":"83","author":"Zhu","year":"2023","journal-title":"Cancer Res."},{"issue":"12_Supplement","key":"10.1016\/j.ijbiomac.2025.143557_bb0490","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1538-7445.AM2022-1087","article-title":"Development and characterization of a bispecific antibody (GB265) against PD-L1 and TIGIT","volume":"82","author":"Huang","year":"2022","journal-title":"Cancer Res."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025041091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025041091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:57:14Z","timestamp":1782903434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025041091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":98,"alternative-id":["S0141813025041091"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143557","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-cell immunoglobulin and ITIM domain as a target in combo anti-PD-(L)1 cancer therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"143557"}}